Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice
- PMID: 7578393
- DOI: 10.1089/hum.1995.6.5-553
Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice
Abstract
The fate of plasmid DNA complexed with cationic lipids delivered intravenously in mice was evaluated at selected timepoints up to 6 months postinjection. Blood half-life and tissue distribution of plasmid DNA and potential expression in tissues were examined. Southern blot analyses of blood indicated that intact plasmid DNA was rapidly degraded, with a half-life of less than 5 min for intact plasmid, and was no longer detectable at 1 hr postinjection. Southern analyses of tissue demonstrated that intact DNA was differentially retained in the lung, spleen, liver, heart, kidney, marrow, and muscle up to 24 hr postinjection. After 7 days, no intact plasmid DNA was detectable by Southern blot analysis; however, the plasmid was detectable by the polymerase chain reaction (PCR) in all tissues examined at 7 and 28 days postinjection. At 6 months postinjection, femtogram levels of plasmid were detected only in muscle. Immunohistochemical analyses did not detect encoded protein in the tissues harboring residual plasmid at 1 or 7 days postinjection.
Comment in
-
Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial.Hum Gene Ther. 1995 May;6(5):549-50. doi: 10.1089/hum.1995.6.5-549. Hum Gene Ther. 1995. PMID: 7578391 No abstract available.
-
Assessing risk.Hum Gene Ther. 1995 May;6(5):551-2. doi: 10.1089/hum.1995.6.5-551. Hum Gene Ther. 1995. PMID: 7578392 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical